1 of 4
FEATURED COMPANIES
- Abbott Laboratories
- Bayer AG
- Empire Genomics LLC
- Illumina, Inc.
- Myriad Genetics Inc.
- Oneome LLC
- MORE
The Asia Pacific Pharmacogenomics Market is expected to witness market growth of 10.2% CAGR during the forecast period (2019–2025).
The study of pharmacogenomics deals with the role of genes in drug response in individuals. The growing number of pharmacogenomics-based tests, which are a result of the growing ailments like cancer, tuberculosis, Alzheimer's disease, cardiovascular diseases, and other diseases, is expected to push the market growth. Pharmacogenomics has observed an exponential growth rate in recent years, owing to a rise in preference of patients towards personalized therapy-based medications.
The major factors boosting the growth of pharmacogenomics include technological advancements in molecular diagnostics, such as several molecular biology techniques including polymerase chain reaction, sequencing, microarrays, electrophoresis, mass spectrometry among others, a surge in the preference for using personalized therapy.
Based on Technology, the market is segmented into Sequencing, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Microarray and Others. Based on Application, the market is segmented into Oncology, Psychiatry, Infectious Diseases, Neurological Diseases, Pain management, Cardiovascular Diseases and Others. Based on End User, the market is segmented into Hospitals and Clinics, Research Institutions, and Academic Institutes. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.
Scope of the Study
Market Segmentation:
By Application
The study of pharmacogenomics deals with the role of genes in drug response in individuals. The growing number of pharmacogenomics-based tests, which are a result of the growing ailments like cancer, tuberculosis, Alzheimer's disease, cardiovascular diseases, and other diseases, is expected to push the market growth. Pharmacogenomics has observed an exponential growth rate in recent years, owing to a rise in preference of patients towards personalized therapy-based medications.
The major factors boosting the growth of pharmacogenomics include technological advancements in molecular diagnostics, such as several molecular biology techniques including polymerase chain reaction, sequencing, microarrays, electrophoresis, mass spectrometry among others, a surge in the preference for using personalized therapy.
Based on Technology, the market is segmented into Sequencing, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Microarray and Others. Based on Application, the market is segmented into Oncology, Psychiatry, Infectious Diseases, Neurological Diseases, Pain management, Cardiovascular Diseases and Others. Based on End User, the market is segmented into Hospitals and Clinics, Research Institutions, and Academic Institutes. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Empire Genomics LLC, Illumina, Inc., oneome LLC, Myriad Genetics Inc., Thermo Fisher Scientific, Inc., Teva Pharmaceuticals Industries Ltd., Bayer AG, Opko Health, Inc., and Becton, Dickinson and Company.
Scope of the Study
Market Segmentation:
By Application
- Sequencing
- Polymerase Chain Reaction
- Electrophoresis
- Mass Spectrometry
- Microarray
- Others
- Oncology
- Psychiatry
- Infectious Diseases
- Neurological Diseases
- Pain management
- Cardiovascular Diseases
- Others
- Hospitals and Clinics
- Research Institutions
- Academic Institutes
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- Abbott Laboratories
- Empire Genomics LLC
- Illumina, Inc.
- Oneome LLC
- Myriad Genetics Inc.
- Thermo Fisher Scientific, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bayer AG
- Opko Health, Inc.
- Becton, Dickinson and Company
Note: Product cover images may vary from those shown
2 of 4
FEATURED COMPANIES
- Abbott Laboratories
- Bayer AG
- Empire Genomics LLC
- Illumina, Inc.
- Myriad Genetics Inc.
- Oneome LLC
- MORE
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Pharmacogenomics Market, by Application
1.4.2 Asia Pacific Pharmacogenomics Market, by Application
1.4.3 Asia Pacific Pharmacogenomics Market, by End User
1.4.4 Asia Pacific Pharmacogenomics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Pharmacogenomics Market by Technology
3.1.1 Asia Pacific Sequencing Market by Country
3.1.2 Asia Pacific Polymerase Chain Reaction Market by Country
3.1.3 Asia Pacific Electrophoresis Market by Country
3.1.4 Asia Pacific Mass Spectrometry Market by Country
3.1.5 Asia Pacific Microarray Market by Country
3.1.6 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Pharmacogenomics Market by Application
4.1.1 Asia Pacific Oncology Market by Country
4.1.2 Asia Pacific Psychiatry Market by Country
4.1.3 Asia Pacific Infectious Diseases Market by Country
4.1.4 Asia Pacific Neurological Diseases Market by Country
4.1.5 Asia Pacific Pain Management Market by Country
4.1.6 Asia Pacific Cardiovascular Diseases Market by Country
4.1.7 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Pharmacogenomics Market by End User
5.1.1 Asia Pacific Hospitals and Clinics Market by Country
5.1.2 Asia Pacific Research Institutions Market by Country
5.1.3 Asia Pacific Academic Institutes Market by Country
Chapter 6. Asia Pacific Pharmacogenomics Market by Country
6.1 China Pharmacogenomics Market
6.1.1 China Pharmacogenomics Market by Technology
6.1.2 China Pharmacogenomics Market by Application
6.1.3 China Pharmacogenomics Market by End User
6.2 Japan Pharmacogenomics Market
6.2.1 Japan Pharmacogenomics Market by Technology
6.2.2 Japan Pharmacogenomics Market by Application
6.2.3 Japan Pharmacogenomics Market by End User
6.3 India Pharmacogenomics Market
6.3.1 India Pharmacogenomics Market by Technology
6.3.2 India Pharmacogenomics Market by Application
6.3.3 India Pharmacogenomics Market by End User
6.4 South Korea Pharmacogenomics Market
6.4.1 South Korea Pharmacogenomics Market by Technology
6.4.2 South Korea Pharmacogenomics Market by Application
6.4.3 South Korea Pharmacogenomics Market by End User
6.5 Singapore Pharmacogenomics Market
6.5.1 Singapore Pharmacogenomics Market by Technology
6.5.2 Singapore Pharmacogenomics Market by Application
6.5.3 Singapore Pharmacogenomics Market by End User
6.6 Malaysia Pharmacogenomics Market
6.6.1 Malaysia Pharmacogenomics Market by Technology
6.6.2 Malaysia Pharmacogenomics Market by Application
6.6.3 Malaysia Pharmacogenomics Market by End User
6.7 Rest of Asia Pacific Pharmacogenomics Market
6.7.1 Rest of Asia Pacific Pharmacogenomics Market by Technology
6.7.2 Rest of Asia Pacific Pharmacogenomics Market by Application
6.7.3 Rest of Asia Pacific Pharmacogenomics Market by End User
Chapter 7. Company Profiles
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Collaborations, partnerships and agreements:
7.1.5.2 Product launches:
7.1.5.3 Acquisition and mergers:
7.1.6 SWOT Analysis
7.2 Empire Genomics LLC
7.2.1 Company Overview
7.3 Illumina, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional& Segmental Analysis
7.3.4 Research& Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Collaborations, partnerships and agreements:
7.3.5.2 Product launches:
7.3.5.3 Acquisition and mergers:
7.4 OneOme LLC
7.4.1 Company Overview
7.5 Myriad Genetics Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Product launches:
7.6 Thermo Fischer Scientific, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.6.6 SWOT Analysis
7.7 Teva Pharmaceuticals Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product launches:
7.8 Bayer AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.8.6 SWOT Analysis
7.9 Opko Health, Inc. (GeneDx, Inc.)
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expense
7.9.4 Recent strategies and developments:
7.9.4.1 Collaborations, partnerships and agreements:
7.9.4.2 Product launches:
7.1 Becton, Dickinson and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Collaborations, partnerships and agreements:
7.10.5.2 Acquisition and mergers:
7.10.5.3 Product launches:
7.10.6 SWOT Analysis
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Pharmacogenomics Market, by Application
1.4.2 Asia Pacific Pharmacogenomics Market, by Application
1.4.3 Asia Pacific Pharmacogenomics Market, by End User
1.4.4 Asia Pacific Pharmacogenomics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Asia Pacific Pharmacogenomics Market by Technology
3.1.1 Asia Pacific Sequencing Market by Country
3.1.2 Asia Pacific Polymerase Chain Reaction Market by Country
3.1.3 Asia Pacific Electrophoresis Market by Country
3.1.4 Asia Pacific Mass Spectrometry Market by Country
3.1.5 Asia Pacific Microarray Market by Country
3.1.6 Asia Pacific Others Market by Country
Chapter 4. Asia Pacific Pharmacogenomics Market by Application
4.1.1 Asia Pacific Oncology Market by Country
4.1.2 Asia Pacific Psychiatry Market by Country
4.1.3 Asia Pacific Infectious Diseases Market by Country
4.1.4 Asia Pacific Neurological Diseases Market by Country
4.1.5 Asia Pacific Pain Management Market by Country
4.1.6 Asia Pacific Cardiovascular Diseases Market by Country
4.1.7 Asia Pacific Others Market by Country
Chapter 5. Asia Pacific Pharmacogenomics Market by End User
5.1.1 Asia Pacific Hospitals and Clinics Market by Country
5.1.2 Asia Pacific Research Institutions Market by Country
5.1.3 Asia Pacific Academic Institutes Market by Country
Chapter 6. Asia Pacific Pharmacogenomics Market by Country
6.1 China Pharmacogenomics Market
6.1.1 China Pharmacogenomics Market by Technology
6.1.2 China Pharmacogenomics Market by Application
6.1.3 China Pharmacogenomics Market by End User
6.2 Japan Pharmacogenomics Market
6.2.1 Japan Pharmacogenomics Market by Technology
6.2.2 Japan Pharmacogenomics Market by Application
6.2.3 Japan Pharmacogenomics Market by End User
6.3 India Pharmacogenomics Market
6.3.1 India Pharmacogenomics Market by Technology
6.3.2 India Pharmacogenomics Market by Application
6.3.3 India Pharmacogenomics Market by End User
6.4 South Korea Pharmacogenomics Market
6.4.1 South Korea Pharmacogenomics Market by Technology
6.4.2 South Korea Pharmacogenomics Market by Application
6.4.3 South Korea Pharmacogenomics Market by End User
6.5 Singapore Pharmacogenomics Market
6.5.1 Singapore Pharmacogenomics Market by Technology
6.5.2 Singapore Pharmacogenomics Market by Application
6.5.3 Singapore Pharmacogenomics Market by End User
6.6 Malaysia Pharmacogenomics Market
6.6.1 Malaysia Pharmacogenomics Market by Technology
6.6.2 Malaysia Pharmacogenomics Market by Application
6.6.3 Malaysia Pharmacogenomics Market by End User
6.7 Rest of Asia Pacific Pharmacogenomics Market
6.7.1 Rest of Asia Pacific Pharmacogenomics Market by Technology
6.7.2 Rest of Asia Pacific Pharmacogenomics Market by Application
6.7.3 Rest of Asia Pacific Pharmacogenomics Market by End User
Chapter 7. Company Profiles
7.1 ABBOTT Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 Recent strategies and developments:
7.1.5.1 Collaborations, partnerships and agreements:
7.1.5.2 Product launches:
7.1.5.3 Acquisition and mergers:
7.1.6 SWOT Analysis
7.2 Empire Genomics LLC
7.2.1 Company Overview
7.3 Illumina, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional& Segmental Analysis
7.3.4 Research& Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Collaborations, partnerships and agreements:
7.3.5.2 Product launches:
7.3.5.3 Acquisition and mergers:
7.4 OneOme LLC
7.4.1 Company Overview
7.5 Myriad Genetics Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Collaborations, partnerships and agreements:
7.5.5.2 Product launches:
7.6 Thermo Fischer Scientific, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expense
7.6.5 Recent strategies and developments:
7.6.5.1 Collaborations, partnerships and agreements:
7.6.5.2 Acquisition and mergers:
7.6.6 SWOT Analysis
7.7 Teva Pharmaceuticals Industries Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Product launches:
7.8 Bayer AG
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Collaborations, partnerships and agreements:
7.8.6 SWOT Analysis
7.9 Opko Health, Inc. (GeneDx, Inc.)
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Research & Development Expense
7.9.4 Recent strategies and developments:
7.9.4.1 Collaborations, partnerships and agreements:
7.9.4.2 Product launches:
7.1 Becton, Dickinson and Company
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
7.10.5 Recent strategies and developments:
7.10.5.1 Collaborations, partnerships and agreements:
7.10.5.2 Acquisition and mergers:
7.10.5.3 Product launches:
7.10.6 SWOT Analysis
Note: Product cover images may vary from those shown
3 of 4
- Abbott Laboratories
- Empire Genomics LLC
- Illumina, Inc.
- Oneome LLC
- Myriad Genetics Inc.
- Thermo Fisher Scientific, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bayer AG
- Opko Health, Inc.
- Becton, Dickinson and Company
Note: Product cover images may vary from those shown
4 of 4
LOADING...
